MI
-
CURE Trial: Clopidogrel Plus Aspirin in Patients With NSTEMI/Unstable Angina
The CURE trial was a landmark randomized clinical trial that evaluated whether adding clopidogrel to aspirin improves outcomes in patients with non–ST-elevation acute coronary syndrome, including NSTEMI and unstable angina. The main finding was: clopidogrel plus aspirin reduced cardiovascular death, nonfatal MI, or stroke, but increased major bleeding. Background Patients with NSTEMI or unstable angina…
-
TRITON-TIMI 38 Trial: Prasugrel vs Clopidogrel in Acute Coronary Syndromes
The TRITON-TIMI 38 trial was a major randomized clinical trial comparing prasugrel with clopidogrel in patients with acute coronary syndrome who were scheduled to undergo PCI. The main finding was: prasugrel reduced ischemic cardiovascular events compared with clopidogrel, but increased bleeding risk. Background Patients with acute coronary syndrome are at high risk for recurrent cardiovascular…
-
PLATO Trial: Ticagrelor vs Clopidogrel in Acute Coronary Syndromes
The PLATO trial was a landmark cardiovascular trial comparing ticagrelor with clopidogrel in patients presenting with acute coronary syndrome. The main finding was clear: ticagrelor reduced cardiovascular death, myocardial infarction, or stroke compared with clopidogrel, without a significant increase in major bleeding. Background Patients with acute coronary syndrome, including STEMI and non-STEMI, are at high…
-
PEGASUS-TIMI 54 Trial: Long-Term Ticagrelor After Prior Myocardial Infarction
The PEGASUS-TIMI 54 trial was a major randomized clinical trial that evaluated whether long-term treatment with ticagrelor, added to aspirin, reduces cardiovascular events in patients with a prior myocardial infarction. The key finding was straightforward: ticagrelor reduced cardiovascular death, myocardial infarction, or stroke, but increased major bleeding. Background Patients who have had a myocardial infarction…
-
COMPLETE Trial: Complete Revascularization After STEMI With Multivessel CAD
The COMPLETE trial was a landmark randomized clinical trial that evaluated whether patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease benefit from complete revascularization rather than treating only the culprit lesion. The key finding was clear: complete revascularization with multivessel PCI reduced major cardiovascular events compared with culprit-lesion-only PCI. Background In…